SANOFI (SAN.PA) Stock Price & Overview

EPA:SANFR0000120578

Current stock price

77.765 EUR
-0.03 (-0.03%)
Last:

The current stock price of SAN.PA is 77.765 EUR. Today SAN.PA is down by -0.03%. In the past month the price decreased by -2.25%. In the past year, price decreased by -26.5%.

SAN.PA Key Statistics

52-Week Range74.85 - 106.2
Current SAN.PA stock price positioned within its 52-week range.
1-Month Range74.85 - 82.2
Current SAN.PA stock price positioned within its 1-month range.
Market Cap
187.809B
P/E
9.94
Fwd P/E
9.17
EPS (TTM)
7.82
Dividend Yield
5.27%

SAN.PA Stock Performance

Today
-0.03%
1 Week
+1.83%
1 Month
-2.25%
3 Months
-5.57%
Longer-term
6 Months -3.32%
1 Year -26.50%
2 Years -14.48%
3 Years -22.40%
5 Years -7.67%
10 Years +9.78%

SAN.PA Stock Chart

SANOFI / SAN Daily stock chart

SAN.PA Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to SAN.PA. When comparing the yearly performance of all stocks, SAN.PA is a bad performer in the overall market: 86.61% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SAN.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to SAN.PA. SAN.PA has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SAN.PA Earnings

On January 29, 2026 SAN.PA reported an EPS of 1.53 and a revenue of 11.30B. The company beat EPS expectations (4.58% surprise) and missed revenue expectations (-2.08% surprise).

Next Earnings DateApr 23, 2026
Last Earnings DateJan 29, 2026
PeriodQ4 / 2025
EPS Reported€1.53
Revenue Reported11.303B
EPS Surprise 4.58%
Revenue Surprise -2.08%

SAN.PA Forecast & Estimates

30 analysts have analysed SAN.PA and the average price target is 98.37 EUR. This implies a price increase of 26.5% is expected in the next year compared to the current price of 77.765.

For the next year, analysts expect an EPS growth of 8.41% and a revenue growth 6.58% for SAN.PA


Analysts
Analysts76
Price Target98.37 (26.5%)
EPS Next Y8.41%
Revenue Next Year6.58%

SAN.PA Groups

Sector & Classification

SAN.PA Financial Highlights

Over the last trailing twelve months SAN.PA reported a non-GAAP Earnings per Share(EPS) of 7.82. The EPS increased by 1.82% compared to the year before.


Income Statements
Revenue(TTM)70.49B
Net Income(TTM)12.49B
Industry RankSector Rank
PM (TTM) 17.71%
ROA 9.85%
ROE 17.49%
Debt/Equity 0.22
Chartmill High Growth Momentum
EPS Q2Q%16.79%
Sales Q2Q%7%
EPS 1Y (TTM)1.82%
Revenue 1Y (TTM)5.29%

SAN.PA Ownership

Ownership
Inst Owners46.23%
Shares2.42B
Float2.14B
Ins Owners0.02%
Short Float %N/A
Short RatioN/A

About SAN.PA

Company Profile

SAN logo image Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 76,493 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Company Info

IPO: 2002-07-01

SANOFI

46 Avenue de la Grande Armee

Paris ILE-DE-FRANCE FR

Employees: 82878

SAN Company Website

SAN Investor Relations

Phone: 33153774000

SANOFI / SAN.PA FAQ

Can you describe the business of SANOFI?

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 76,493 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.


Can you provide the latest stock price for SANOFI?

The current stock price of SAN.PA is 77.765 EUR. The price decreased by -0.03% in the last trading session.


What is the dividend status of SANOFI?

SANOFI (SAN.PA) has a dividend yield of 5.27%. The yearly dividend amount is currently 3.79.


What is the ChartMill rating of SANOFI stock?

SAN.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


Can you provide the sector and industry classification for SANOFI?

SANOFI (SAN.PA) operates in the Health Care sector and the Pharmaceuticals industry.


What is the employee count for SAN stock?

SANOFI (SAN.PA) currently has 82878 employees.


What is the next earnings date for SAN stock?

SANOFI (SAN.PA) will report earnings on 2026-04-23.